secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139053
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma faces FDA AdCom on May 11 for neffy (intranasal epinephrine); PK/PD sufficiency debated
--------------------------------------------------------------------------------

- FDA AdCom to discuss whether PK/PD data for ARS-1 (intranasal epinephrine) sufficiently establish efficacy for anaphylaxis; meeting scheduled May 11, 2023.
- Development program relies on PK/PD similarity to injection products rather than clinical efficacy trials; FDA questions translatability to anaphylaxis patients.
- FDA notes PK/PD discrepancy: ARS-1 has lower epinephrine PK than EpiPen but higher/more sustained SBP/PR response; ARS argues this supports efficacy.
- Proposed dose: 2 mg intranasal (one spray) for adults and children ≥30 kg, with optional second dose after 10 minutes if needed.
- Human factors validation studies support usability; committee asked to weigh benefit-risk considering needle-free alternative to injectable epinephrine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523139053/0001193125-23-139053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523139053/d415087d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer